Management Of Essential Tremor Research Articles

Present and Prospective Advancements in the Field of Deep Brain Stimulation Technology

Deep brain stimulation (DBS) in the neurosurgery domain allows for precise control of particular neural circuits. DBS has shown significant therapeutic effectiveness in the management of essential tremor, dystonia, and Parkinson's disease (PD). Moreover, ongoing research is investigating the potential of DBS as a therapy modality for several additional conditions characterized by aberrant circuitry, including depression and dementia. Over the last two decades, there has been a gradual improvement in DBS (Deep Brain Stimulation) devices, which today integrate an extension wire, pulse generator, and intracranial electrode. These components have been borrowed from the field of cardiology. The present paradigm of DBS is expected to undergo significant changes due to recent breakthroughs in technology and imaging, as well as a more comprehensive understanding of brain illnesses. Anticipated advancements in the tolerability and efficacy of DBS may be attributed to progress made in several areas, including battery and electrodes designing, stimulation systems, on-demand and closed-loop stimulation, including sensor technologies. This review provides a comprehensive examination of the historical and projected trajectory of DBS technology. By retrospectively examining the progress of DBS, we may enhance our understanding and recognition of our current position, as well as proactively forecast the next obstacles and prospects.

Tremors

Tremor is the most common movement disorder and denotes a rhythmic and involuntary movement of one or several regions of the body. This review covers disease definition, essential tremor, enhanced physiologic tremor, parkinsonian tremor, dystonic tremor, orthostatic tremor, cerebellar tremor, Holmes tremor, neuropathic tremor, palatal tremor, drug-induced and toxic tremors, functional tremor, rare tremor syndromes, tremorlike conditions, and treatment of tremor. Figures show action tremor assessment, the central nervous system circuits of tremor, magnetic resonance imaging findings in specific tremor conditions, general management of tremor patients, an algorithm for the treatment of parkinsonian tremor, and an algorithm for the treatment of dystonic tremor and primary writing tremor. Tables list types of tremor according to the condition of activation, tremor conditions in newborns and during childhood, clinical features of the most common tremor syndromes, motor signs other than tremor and nonmotor features of essential tremor patients, Movement Disorder Society consensus criteria for the diagnosis of essential tremor, genetic and environmental causes of essential tremor, causes of enhanced physiologic tremor, drugs and toxins known to cause tremor, paroxysmal tremors, pseudorhythmic myoclonus in the differential diagnosis of tremor, and pharmacologic management of essential tremor. Key words: essential tremor, movement disorder, pathologic tremor, physiologic tremor, tremor This review contains 6 highly rendered figures, 7 videos, 11 tables, and 163 references.

Diagnosis and management of essential tremor

Essential tremor (ET) is the most common extrapyramidal disease and one of the most frequent neurological diseases. The main presentation of ET is a progressive bilateral (kinetic-postural) hand tremor. The prevalence in people over 65 years is 5%, it increases with age up to 22% in people over 95 years. About half of patients with ET have family history. The modern concepts of the pathogenesis, clinical features and differential diagnosis are considered. Possible methods of medical and surgical management are described.

Essential Tremor: β blockers a first-line therapy

Essential tremor is one of the most common movement disorders in adults and can affect both children and adults. Tremor may also be present in other locations, commonly the neck or the vocal cords. Patients with additional neurologic symptoms are now categorized as “essential tremor plus.” Additional clinical features associated with the condition include but are not limited to cognitive impairment, psychiatric disorders, and hearing loss. When treatment is needed, propranolol is considered a first-line treatment in the management of essential tremor.

Botulinum Toxin in Management of Limb Tremor.

Essential tremor is characterized by persistent, usually bilateral and symmetric, postural or kinetic activation of agonist and antagonist muscles involving either the distal or proximal upper extremity. Quality of life is often affected and one’s ability to perform daily tasks becomes impaired. Oral therapies, including propranolol and primidone, can be effective in the management of essential tremor, although adverse effects can limit their use and about 50% of individuals lack response to oral pharmacotherapy. Locally administered botulinum toxin injection has become increasingly useful in the management of essential tremor. Targeting of select muscles with botulinum toxin is an area of active research, and muscle selection has important implications for toxin dosing and functional outcomes. The use of anatomical landmarks with palpation, EMG guidance, electrical stimulation, and ultrasound has been studied as a technique for muscle localization in toxin injection. Earlier studies implemented a standard protocol for the injection of (predominantly) wrist flexors and extensors using palpation and EMG guidance. Targeting of muscles by selection of specific activators of tremor (tailored to each patient) using kinematic analysis might allow for improvement in efficacy, including functional outcomes. It is this individualized muscle selection and toxin dosing (requiring injection within various sites of a single muscle) that has allowed for success in the management of tremors.

Zonisamide for the Management of Essential Tremor: An Illustrative Case Report on Long-Term Effectiveness

Essential tremor, a common adult pathologic tremor disorder, is characterized by action tremors. Mainstays of treatment include gabapentin, primidone, and propranolol. However, many patients obtain insufficient benefit or do not tolerate these medications (especially the elderly). Short-term studies demonstrate that zonisamide may be effective for essential tremor; however, long-term data are lacking. This is a case report of an 83-year-old, right-handed man with essential tremor of the upper extremities and head who previously failed several pharmacological treatments (defined as obtaining inadequate benefit from maximum tolerated dose) with gabapentin, nadalol, propranolol, and primidone and was initiated on zonisamide monotherapy. Long-term zonisamide therapy (200 mg daily) was well tolerated in this elderly patient and associated with clinically significant improvement of upper extremity tremor and clinically modest improvement in head tremor. The beneficial effects and tolerability were sustained over nearly 28 months of follow-up treatment.

Essential Tremor: A Comprehensive Overview

Essential tremor is the most prevalent form of movement disorders in the world and is 10 times more prevalent than that of Parkinson’s disease. Even though it is traditionally considered as a benign disease all the patients of essential tremor have tremor induced disabilities. Essential tremor which shows kinetic, postural and resting is tremor mimicker of all tremor associated disease so often misdiagnosed and mismanaged. This article is authors’ endeavor to summarize the facts in different publications on essential tremor. Electronic databases like MEDLINE/Pub Med, Google Scholar, IMSEAR (Index Medicus for South-East Asia Region) and Scopemed were extensively searched with MeSH (Medical Subject Headings) terms “essential tremor”, “clinical features” “pathophysiology” and “treatment” from the earliest possible date of 1966 to Feb 2017. Articles in any languages especially those published in recent years were given preference. This review deals mostly with the clinical features and evidence-based management of essential tremor.

Emerging strategies in the management of essential tremor.

Currently available therapies for essential tremor (ET) provide sufficient control only for less than a half of patients and many unmet needs exist. This is in part due to the empiric nature of existing treatment options and persisting uncertainties about the pathogenesis of ET. The emerging concept of ET as a possible neurodegenerative disorder, better understanding of associated biochemical changes, including alterations in the γ-aminobutyric acid (GABA)-ergic system and gap junctions, and the identification of the role of the leucine-rich repeat and immunoglobulin-like domain-containing 1 (LINGO-1) gene in ET pathogenesis suggest new avenues for more targeted therapies. Here we review the most promising new approaches to treating ET, including allosteric modulation of GABA receptors and modifications of the LINGO-1 pathway. Medically refractory tremor can be successfully treated by high-frequency deep brain stimulation (DBS) of the ventral intermediate nucleus, but surgical therapies are also fraught with limitations due to adverse effects of stimulation and the loss of therapeutic response. The selection of additional thalamic and extrathalamic targets for electrode placements and the development of a closed-loop DBS system enabling automatic adjustment of stimulation parameters in response to changes in electrophysiologic brain activity are also reviewed. Tremor cancellation methods using exoskeleton and external hand-held devices are also briefly discussed.

Pharmacological Management of Essential Tremor

Pharmacological Management of Essential Tremor

Epidemiology and Management of Essential Tremor in Children

Essential tremor (ET) is a common, often familial, movement disorder characterized by tremor of the limbs, head, and voice. Epidemiological surveys indicate that up to 5% of the adult population has ET, and 5-30% of adults with ET report symptom onset during childhood. There is, however, little published regarding ET in the pediatric population, and no prospective studies targeted specifically to children. Retrospective studies from subspecialty movement disorder clinics indicate that childhood-onset ET is usually hereditary, begins at a mean age of 6 years, and affects boys three times as often as girls. While ET occasionally results in disability during childhood, only one-quarter of children seeing a neurologist for ET require pharmacotherapy. Small case series suggest that propranolol is effective in approximately 50% of children with ET, but controlled treatment trials are lacking.

Epidemiology and Management of Essential Tremor in Children

Epidemiology and Management of Essential Tremor in Children

Review: Diagnosis and management of essential tremor and dystonic tremor

Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of discomfort caused by tremor. For mild tremor, nonpharmacological strategies consist of alcohol and acute pharmacological therapy; for moderate tremor, pharmacological therapies (propranolol, gabapentin, primidone, topiramate, alprazolam and other drugs); and for severe tremor, the role of functional surgery is emphasised (thalamic deep brain stimulation, thalamotomy). The more specific treatment of head tremor with the use of botulinum toxin is also discussed. Several points are discussed to guide the immediate research into this disease in the near future. Dystonic tremor is a common symptom in dystonia. Diagnostic criteria for dystonic tremor and differential diagnosis with psychogenic tremor and ET are described. Treatment of dystonic tremor matches the treatment of dystonia. In cases of symptomatic dystonic tremor similar to ET, therapeutic strategies would be the same as for ET.

Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up

Essential tremor is the most common involuntary movement; we studied 113 affected subjects (54 men, 59 women) with an average age of 63.9 years and average duration of 9.05 years. These patients participated in a double-blind study with a 1-year follow-up to compare treatment efficiency using primidone dosages of 250 mg/day (G 250, 56 patients) versus 750 mg/day (G 750, 57 patients). The study was designed with an 80% power and 95% confidence level. The statistical analysis used was an ANOVA (with Bonferroni multiple comparison test corrections); a value of p<0.004 was accepted as significant. To compare other values, a chi-square test was used; p<0.05 was considered significant. To evaluate the efficacy of the drug, clinical protocol employed the ‘clinical evaluation scale for tremor’. All of the patients were evaluated a total of 13 times, once prior to the introduction of primidone and the other 12 evaluations following the initiation of the treatment. Eighty-seven patients completed the study: 15 patients abandoned the study due to undesirable side effects, five due to negative response, and six who were lost to follow-up. The percentage of patients who didn't complete the study was significantly higher in the group that received 750 mg/day of primidone ( p<0.04) and more frequent as well in this same group, due to undesirable side effects ( p<0.03). The patients of both G250 and G750 showed a significant improvement in each of the controls compared to the basal value ( p<0.0001). No significant differences ( p<0.06) were found when the averages of the evaluations of each group were compared. These responses were maintained during the entire treatment period. Low doses of primidone (250 mg/day) were equally or more effective than high doses (750 mg/day) in the control of essential tremor; this response was maintained for 12 months and furthermore, demonstrated fewer undesirable effects.

Tremor--easily seen but difficult to describe and treat.

Tremor is a common movement disorder yet many physicians struggle with its terminology as well as with its treatment. Attempts have been made to develop standard terminology and criteria for tremors but this process continues to evolve. In this review, a summary of the currently-proposed phenomenology and syndromic classification of all types of tremor is presented. The diagnosis and management of essential tremor is presented in more detail, as it is the most commonly encountered tremor.

Management of essential tremor.

Essential tremor (ET) is the most prevalent tremor syndrome. It commonly affects the hands, head, voice, and other body parts. Appropriate management begins with correct diagnosis. Primidone and propranolol are the first-line medications for the treatment for ET, but several other medications may also provide benefit. In patients with medically refractory tremor, alternative therapies, including surgery or injections of botulinum toxin, may be considered.

The Pharmacological Management of Essential Tremor

The Pharmacological Management of Essential Tremor